Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The award vests in four equal installments of 8,356 units on March 4 of 2027, 2028, 2029, and 2030. The filing notes that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The award vests in four equal installments of 8,356 units on March 4 of 2027, 2028, 2029, and 2030. The filing notes that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised restricted share units into 33,512 ordinary shares and 18,601 ordinary shares at a price of zero per share, increasing his direct holdings. He also received a new grant of 30,385 restricted share units, scheduled to vest in annual installments from March 4, 2027 through March 4, 2030. Each restricted share unit represents a right to one ordinary share or its cash value, and the ordinary shares may be represented by American Depositary Shares.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised restricted share units into 33,512 ordinary shares and 18,601 ordinary shares at a price of zero per share, increasing his direct holdings. He also received a new grant of 30,385 restricted share units, scheduled to vest in annual installments from March 4, 2027 through March 4, 2030. Each restricted share unit represents a right to one ordinary share or its cash value, and the ordinary shares may be represented by American Depositary Shares.
Lippman Evan reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries executive Evan Lippman, EVP of Business Development, received a grant of 27,347 restricted share units (RSUs) on March 4, 2026. Each RSU represents a contingent right to receive either one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share.
The RSUs vest in four annual installments: 6,836 on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 6,839 on March 4, 2030. Following this award, Lippman’s reported derivative holdings from this grant total 27,347 RSUs. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, each currently equal to one ordinary share.
Lippman Evan reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries executive Evan Lippman, EVP of Business Development, received a grant of 27,347 restricted share units (RSUs) on March 4, 2026. Each RSU represents a contingent right to receive either one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share.
The RSUs vest in four annual installments: 6,836 on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 6,839 on March 4, 2030. Following this award, Lippman’s reported derivative holdings from this grant total 27,347 RSUs. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, each currently equal to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported RSU vesting, a new RSU grant, and a small share sale. On March 4, 2026, he exercised 23,251 restricted share units into the same number of ordinary shares at $0.00 per share and received a new award of 50,643 restricted share units.
He then sold 11,277 ordinary shares at a weighted average price of $32.4645 per share in an open-market transaction effected under a Rule 10b5-1 trading plan, with the footnotes stating this sale was to cover tax withholding from the RSU vesting. After these transactions, he directly held 97,590 ordinary shares and 50,643 restricted share units, each RSU representing a contingent right to one ordinary share or its cash value at settlement.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported RSU vesting, a new RSU grant, and a small share sale. On March 4, 2026, he exercised 23,251 restricted share units into the same number of ordinary shares at $0.00 per share and received a new award of 50,643 restricted share units.
He then sold 11,277 ordinary shares at a weighted average price of $32.4645 per share in an open-market transaction effected under a Rule 10b5-1 trading plan, with the footnotes stating this sale was to cover tax withholding from the RSU vesting. After these transactions, he directly held 97,590 ordinary shares and 50,643 restricted share units, each RSU representing a contingent right to one ordinary share or its cash value at settlement.
Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.
Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.
Teva Pharmaceutical Industries’ interim Chief Legal Officer, Brian Savage, reported several equity compensation transactions in Teva ordinary shares and restricted share units on March 4, 2026. He acquired ordinary shares through the vesting and exercise of restricted share units and also received a new restricted share unit award.
On that date he acquired ordinary shares via derivative exercises totaling 4,744 shares and 3,466 shares, and was granted 11,280 restricted share units, each representing a right to one ordinary share or its cash value at settlement. To satisfy tax withholding obligations from these vestings, he sold 1,489 shares and 1,186 shares in open-market transactions at a weighted average price of $32.4645 per share. After these transactions, he directly owned 8,461 ordinary shares.
Teva Pharmaceutical Industries’ interim Chief Legal Officer, Brian Savage, reported several equity compensation transactions in Teva ordinary shares and restricted share units on March 4, 2026. He acquired ordinary shares through the vesting and exercise of restricted share units and also received a new restricted share unit award.
On that date he acquired ordinary shares via derivative exercises totaling 4,744 shares and 3,466 shares, and was granted 11,280 restricted share units, each representing a right to one ordinary share or its cash value at settlement. To satisfy tax withholding obligations from these vestings, he sold 1,489 shares and 1,186 shares in open-market transactions at a weighted average price of $32.4645 per share. After these transactions, he directly owned 8,461 ordinary shares.
Teva Pharmaceutical Industries’ Chief Accounting Officer, Amir Weiss, reported equity-based compensation activity on March 4, 2026. He exercised previously granted restricted share units (RSUs), converting 10,679 RSUs from a 2022 grant and 5,650 RSUs from a 2024 grant into the same number of ordinary shares at no cash cost.
Weiss also received a new award of 11,280 RSUs granted on March 4, 2026, scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030. Following these transactions, he directly owned 27,158 ordinary shares and 11,280 RSUs, reflecting increased equity exposure with no reported share sales.
Teva Pharmaceutical Industries’ Chief Accounting Officer, Amir Weiss, reported equity-based compensation activity on March 4, 2026. He exercised previously granted restricted share units (RSUs), converting 10,679 RSUs from a 2022 grant and 5,650 RSUs from a 2024 grant into the same number of ordinary shares at no cash cost.
Weiss also received a new award of 11,280 RSUs granted on March 4, 2026, scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030. Following these transactions, he directly owned 27,158 ordinary shares and 11,280 RSUs, reflecting increased equity exposure with no reported share sales.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting the sale of 17,295 ordinary shares under Rule 144. The filing references a Restricted Share Unit award vesting dated 03/05/2025 and lists 03/05/2026 and the NYSE in the securities table.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting the sale of 17,295 ordinary shares under Rule 144. The filing references a Restricted Share Unit award vesting dated 03/05/2025 and lists 03/05/2026 and the NYSE in the securities table.
Teva Pharmaceutical Industries Limited filed a Form 144 reporting the proposed sale of 14,150 ordinary shares with an aggregate market value of $448,107.86. The shares are tied to a Restricted Share Unit Award with vesting/acquisition noted 03/05/2025, and the filing shows a transaction date of 03/05/2026, handled through Citigroup Global Markets.
Teva Pharmaceutical Industries Limited filed a Form 144 reporting the proposed sale of 14,150 ordinary shares with an aggregate market value of $448,107.86. The shares are tied to a Restricted Share Unit Award with vesting/acquisition noted 03/05/2025, and the filing shows a transaction date of 03/05/2026, handled through Citigroup Global Markets.